Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,476 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Insulin-Dependent Diabetes Mellitus 1 Clear all
Completed Not applicable Interventional Results available

A Cognitive Behavioral Therapy (CBT) Intervention to Reduce Fear of Hypoglycemia in Type 1 Diabetes

NCT03549104
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Fear Reduction Intervention, Attention Control
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

ADJUnct Semaglutide Treatment in Type 1 Diabetes

NCT05537233
View directory record Official record
Conditions
Type 1 Diabetes, Obesity
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Viral N. Shah
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Aurora, Colorado • West Des Moines, Iowa • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Not applicable Interventional

Hypoglycaemia Awareness Restoration Programme

NCT02940873
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
HARPdoc courses, BGAT courses
Behavioral
Lead sponsor
King's College London
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 14, 2026, 5:17 PM EDT
Recruiting Not applicable Interventional

Telehealth Music Therapy for Adults With Endocrine Disorder and Depression

NCT07413874
View directory record Official record
Conditions
Type 1 Diabetes, Hashimoto Disease, Graves Disease, Addison Disease, Autoimmune Polyglandular Syndrome Type III, Depression, Endocrine System Diseases
Interventions
Telehealth Resource Oriented Music Therapy
Behavioral
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boone, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Results available

Liraglutide in Adolescents With Type 1 Diabetes

NCT02516657
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Liraglutide
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
15 Years to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 14, 2026, 5:17 PM EDT
Approved For Marketing No phase listed Expanded access

Islet Transplantation in Type I Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

NCT03791567
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Donislecel (allogeneic islets of Langerhans for transplant)
Biological
Lead sponsor
CellTrans Inc.
Industry
Eligibility
18 Years to 75 Years
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Not applicable Interventional Results available

Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy

NCT01714505
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Assistant (DiAs)
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Santa Barbara, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Not applicable Interventional Results available

Medtronic Treat to Range (TTR) Closed-Loop Control

NCT01490151
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes, Metabolic and Nutritional Disorders
Interventions
TTR controller (Medtronic)
Device
Lead sponsor
Stanford University
Other
Eligibility
15 Years to 30 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 14, 2026, 5:17 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes

NCT04101045
View directory record Official record
Conditions
Type 1 Diabetes, De Novo Lipogenesis
Interventions
Oral Glucose Tolerance Test
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
13 Years to 22 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Not applicable Interventional Results available

Testing State of the Art Remote Glucose Monitoring at Diabetes Camp

NCT01680653
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Mini-glucagon, Remote monitoring, Carbohydrates
Drug · Device · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 21 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Not applicable Interventional Results available

Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)

NCT05422053
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
t:slim X2 insulin pump with Control-IQ technology 1.5
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Idaho Falls, Idaho • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 14, 2026, 5:17 PM EDT
Recruiting Phase 2 Interventional

The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes

NCT06976619
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Liraglutide Pen Injector, Saline Injections
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Not applicable Interventional Results available

Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas

NCT01762059
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Bi-homonal Bionic Pancreas, Usual care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 14, 2026, 5:17 PM EDT
Active, not recruiting Phase 2 Interventional

Probiotics in Newly Diagnosed T1D

NCT04141761
View directory record Official record
Conditions
Type 1 Diabetes, Type1diabetes, Type 1 Diabetes Mellitus
Interventions
Visbiome, Placebo
Dietary Supplement · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus

NCT00938405
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hyperlipidemias
Interventions
Colesevelam HCl, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

R-5280 in Newly Diagnosed Patients With Type 1 Diabetes

NCT06057454
View directory record Official record
Conditions
Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1
Interventions
R-5280, Placebo
Drug · Other
Lead sponsor
Rise Therapeutics LLC
Industry
Eligibility
11 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Plantation, Florida • Rochester, Minnesota • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Phase 4 Interventional

Lantus in the Treatment of Type 1 Diabetes Children

NCT00206401
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Lantus and short acting analogs Vs NPH and short acting analogs
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
6 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 14, 2026, 5:17 PM EDT
Terminated Phase 2 Interventional

Diabetic Gastroparesis Efficacy/Safety Study of TZP-102

NCT01664637
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
10 mg TZP-102, Placebo
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Huntsville, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Phase 1 Interventional Results available

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

NCT03095651
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 14, 2026, 5:17 PM EDT
Completed Phase 3 Interventional

Behavior Therapy for Families of Diabetic Adolescents

NCT00358059
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Behavioral Family Systems Therapy for Diabetes
Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 16 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Jacksonville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2006 · Synced Oct 14, 2026, 5:17 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Expanding Coverage of Continuous Subcutaneous Insulin Infusion in Pediatric Patients With Diabetes

NCT00829062
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Continuous glucose glucose sensor- physician ordered
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Months to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2010 · Synced Oct 14, 2026, 5:17 PM EDT
Recruiting Phase 2 Interventional

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil

NCT06455319
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Anti-thymocyte globulin (ATG), verapamil extended release capsule, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
6 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Aurora, Colorado • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 14, 2026, 5:17 PM EDT
Recruiting Not applicable Interventional

To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.

NCT07287943
View directory record Official record
Conditions
Type 1 Diabetes, Gastroparesis Due to Diabetes Mellitus Type I
Interventions
Medtronic 780G AID
Device
Lead sponsor
Viral N. Shah
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 5:17 PM EDT
Recruiting Not applicable Interventional

Insulin Delivery With Self-Adjusting Closed-Loop and Behavioral Glycemic Control Enhanced by Prediction

NCT07507708
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Automated Insulin Delivery (AID), AIDANET + Fully Closed Loop (FCL), AIDANET + Anticipatory Closed Loop (ACL)
Device
Lead sponsor
Sue Brown
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 14, 2026, 5:17 PM EDT